FDA recall, , Moderate risk
Department of Defense Navy Whole Blood
Whole Blood tested negative for anti-HTLV but was collected from a donor who previously tested reactive.
Recall ended Sep 21, 2026. Still check yours.
Summary by Recall Canary from the FDA notice
What happened
The Department of Defense - Navy recalled Whole Blood distributed in Asia. The blood tested negative for the antibody to the Human T-Lymphotropic Virus (Anti-HTLV) but was collected from a donor who previously tested repeatedly reactive for anti-HTLV, Western blot positive. The recall began on December 29, 2025 and was added to the FDA's Enforcement Report on September 21, 2026.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Compare these details with yours, then check the recall notice to see which units are recalled.
Whole Blood
Recall details
- Company began the recall
- Sold in
Asia
- Company
- Department of Defense - Navy
- Hazard
- Blood donor screening
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99647
- Recall number
- B-0240-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA · Recall ended
In FDA's weekly enforcement report
Listed on Recall Canary
